Protocol IM119-013: A Phase IIa randomised, double-blind, placebo controlled study to evaluate the clinical efficacy, safety and pharmacokinetics of three different doses of BMS 582949 given orally... (2008)

Grant type:
Bristol-Myers Squibb Pharmaceuticals Pty Limited
Researchers:
  • NHMRC Practitioner Fellow
    The University of Queensland Diamantina Institute
    Faculty of Medicine
Funded by:
Bristol-Myers Squibb Pharmaceuticals Pty Limited